What are the challenges in commercial non-tuberculous mycobacteria (NTM) drug discovery and how should we move forward?
Expert Opin Drug Discov
; 15(1): 7-9, 2020 01.
Article
em En
| MEDLINE
| ID: mdl-31566439
ABSTRACT
Introduction:
Despite the great clinical need, the development of drugs for treating non-tuberculous mycobacteria lung disease (NTM-LD), partly from the scientific difficulty, but also because the eventual size and types of markets for commercially-developed drugs has been unclear.Areas Covered Here, key questions regarding the markets for commercial NTM-LD drugs are discussed, together with potential solutions for resolving these questions.Expert Opinion Many of these questions will become better resoled over time, but uncertainties will remain around likely competition and whether approval and reimbursement will be achieved for all NTM-LD or smaller subsections of the market. Additionally, both 'push' and 'pull' incentives should be considered by policymakers to ensure the NTM-LD market is successfully addressed.Palavras-chave
Texto completo:
1
Temas:
ECOS
/
Aspectos_gerais
Bases de dados:
MEDLINE
Assunto principal:
Descoberta de Drogas
/
Antibacterianos
/
Micobactérias não Tuberculosas
/
Infecções por Mycobacterium não Tuberculosas
Tipo de estudo:
Incidence_studies
/
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Opin Drug Discov
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Estados Unidos